Individualisierte Medizin in der Diagnostik und prognostischen Einsch?tzung in der akuten myeloischen Leuk?mie mit normalem Karyotyp bei Erwachsenen unter 65 Jahren: eine systematische Literaturrecherche und Metaanalyse zu FLT3-ITD

详细信息    查看全文

• 作者：PD Dr. med. Matthias Port ; Miriam B?ttcher ; Dr. med. Felicitas Thol…
• 关键词：Akute myeloische Leuk?mie ; Normaler Karyotyp ; Personalisierte Medizin ; FLT3 ; ITD ; Acute myeloid leukemia ; Normal karyotype ; Personalized medicine ; FLT3 ; ITD
• 刊名：Ethik in der Medizin
• 出版年：2013
• 出版时间：September 2013
• 年：2013
• 卷：25
• 期：3
• 页码：183-193
• 全文大小：629KB
• 参考文献：1. Arber DA, Brunning RD, Le Beau MM et al (2007) Acute myeloid leukaemia and related precursor neoplasms. In: Swerdlow SH (Hrsg) WHO classification of tumours of haematopoietic and lymphoid tissues, 4. Aufl. IARC Press, Lyon, S?109-66
  2. Bareschino MA, Schettino C, Rossi A et al (2011) Treatment of advanced non small cell lung cancer. J Thorac Dis 3:122-33. doi:10.3978/j.issn.2072-1439.2010.12.08
  3. Boissel N, Renneville A, Biggio V et al (2005) Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood 106:3618-620. doi:10.1182/blood-2005-05-2174
  4. Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-516. doi:10.1056/NEJMoa1103782
  5. Damm F, Heuser M, Morgan M et al (2010) Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. J Clin Oncol 28:578-85. doi:10.1200/JCO.2009.23.0342
  6. Damm F, Heuser M, Morgan M et al (2011) Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. Blood 117:4561-568. doi:10.1182/blood-2010-08-303479
  7. D?hner K, Schlenk RF, Habdank M et al (2005) Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 106:3740-746. doi:10.1182/blood-2005-05-2164
  8. D?hner K, D?hner H (2008) Molecular characterization of acute myeloid leukemia. Haematologica 93:976-82 f="http://dx.doi.org/10.3324/haematol.13345">CrossRef
  9. Dunna NR, Rajappa S, Digumarti R et al (2010) Fms like tyrosine kinase (FLT3) and nucleophosmin 1 (NPM1) mutations in de novo normal karyotype acute myeloid leukemia (AML). Asian Pac J Cancer Prev 11:1811-816
  10. Fr?hling S, Schlenk RF, Stolze I et al (2004) CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 22:624-33. doi:10.1200/JCO.2004.06.060
  11. Gale RE, Green C, Allen C et al (2008) The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 111:2776-784 f="http://dx.doi.org/10.1182/blood-2007-08-109090">CrossRef
  12. Grimwade D, Hills RK, Moorman AV et al (2010) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116:354-65 f="http://dx.doi.org/10.1182/blood-2009-11-254441">CrossRef
  13. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646-74. doi:10.1016/j.cell.2011.02.013
  14. Heuser M, Beutel G, Krauter J et al (2006) High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood 108:3898-905. doi:10.1182/blood-2006-04-014845
  15. Kim YK, Kim HJN, Lee SR et al (2010) Prognostic significance of nucleophosmin mutations and FLT3 internal tandem duplication in adult patients with cytogenetically normal acute myeloid leukemia. Korean J Hematol 45:36-5 f="http://dx.doi.org/10.5045/kjh.2010.45.1.36">CrossRef
  16. Langer C, Radmacher MD, Ruppert AS et al (2008) High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Blood 111:5371-379. doi:10.1182/blood-2007-11-124958
  17. Langer C, Marcucci G, Holland KB et al (2009) Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 27:3198-204. doi:10.1200/JCO.2008.20.6110
  18. Marcucci G, Maharry K, Radmacher MD et al (2008) Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B study. J Clin Oncol 26:5078-087. doi:10.1200/JCO.2008.17.5554
  19. Marcucci G, Haferlach T, D?hner H (2011) Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 29:475-86. doi:10.1200/JCO.2010.30.2554
  20. O’Brien SG, Guilhot F, Larson RA et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994-004. doi:10.1056/NEJMoa022457
  21. Paschka P, Marcucci G, Ruppert AS et al (2008) Wilms-tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 26:4595-602. doi:10.1200/JCO.2007.15.2058
  22. Schlenk RF, D?hner K, Krauter JJ et al (2008) Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358:1909-918. doi:10.1056/NEJMoa074306
  23. Taskesen E, Bullinger L, Corbacioglu A et al (2010) Prognostic impact, concurrent genetic mutations and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood 117:2469-475. doi:10.1182/blood-2010-09-307280
  24. Thiede C, Koch S, Creutzig E et al (2006) Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 107:4011-020. doi:10.1182/blood-2005-08-3167
  25. Vardiman JW, Thiele J, Arber DA et al (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937-51. doi:10.1182/blood-2009-03-209262
  26. Virappane P, Gale R, Hills R et al (2008) Mutation of the Wilms-tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 26:5429-435. doi:10.1200/JCO.2008.16.0333
  27. Wagner K, Damm F, Goehring G et al (2010) Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol 28:2356-364. doi:10.1200/JCO.2009.27.6899
  28. Whitman SP, Ruppert AS, Radmacher MD et al (2008) FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood 111:1552-559. doi:10.1182/blood-2007-08-107946
  29. Yanada M, Matsuo K, Suzuki T, Kiyoi H, Naoe T (2005) Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Leukemia 19:1345-349. doi:10.1038/sj.leu.2403838
  
• 作者单位：PD Dr. med. Matthias Port (1)
  Miriam B?ttcher (1)
  Dr. med. Felicitas Thol (1)
  Nicole Trachte (2)
  Prof. Dr. Jürgen Wasem (2)
  Prof. Dr. med. Arnold Ganser (1)
  Laura Pouryamout M.A. (2)
  Dr. med. Dr. rer. pol. Anja Neumann (2)
  
  1. Klinik für H?matologie, H?mostaseologie, Onkologie und Stammzelltransplantation, Medizinische Hochschule Hannover, Carl Neubergstr. 1, 30625, Hannover, Deutschland
  2. Lehrstuhl für Medizinmanagement, Universit?t Duisburg-Essen, Campus Essen, Essen, Deutschland
  
• ISSN：1437-1618

文摘

Introduction Diagnosis and classification of acute myeloid leukemia (AML) is based on cytological criteria and cytogenetic alterations. Individualization of diagnosis and therapy of AML normal karyotype AML (CN-AML) is increasingly possible due to detection of recurrent mutations. In this systematic review and meta-analysis, we examined the mutation FLT3-ITD in CN-AML. Methods A systematic search of all publications listed in the electronic databases Embase, Pubmed, Healthstar, BIOSIS, ISI Web of Knowledge and Cochrane was performed from 2000 up to March 2012 for the mutations fms-related tyrosine kinase 3 (FLT3-ITD) in CN-AML patients aged 15-5 years. The literature search included data extraction, qualitative, and quantitative synthesis of information in terms of a meta-analysis. Results In all, 18 studies were included and qualitatively analyzed for CN-AML. Three studies were included in the quantitative meta-analysis for CN-AML incorporating 1,203 patients. The FLT3-ITD mutation versus wild type showed a statistically significant worse prognosis with a hazard ratio for overall survival of 2.19 for CN-AML. Conclusion FLT3-ITD versus wild type FLT3 is associated with worse prognosis in AML. Diagnostic workup for AML should include mutation analysis of FLT3.